Bank of America
SPRY icon

Bank of America’s ARS Pharmaceuticals SPRY Stock Holding History

Bank of America’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67,000
Closed -$972K – 8400
2024
Q3 		$972K Buy
+67,000
New +$797K ﹤0.01% 5074

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America's SPRY Position: Q1 2026 in Review

Bank of America reduced its ARS Pharmaceuticals (SPRY) stake by 41% in Q1 2026, selling an estimated $1.88M and leaving 285,728 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

Bank of America first reported a position in SPRY in Q1 2021 and has held it in 21 quarters since. The position peaked at $5.68M in Q2 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Bank of America held 285,728 shares of ARS Pharmaceuticals worth $2.29M as of Q1 2026.
  • Bank of America sold 196,356 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.88M.
  • ARS Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4028 holding.
  • Bank of America first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Bank of America's ARS Pharmaceuticals position peaked at $5.68M in Q2 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.